TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Limited cross-variant immunity without vaccination (Nature)
• EUA for boosters in 5-11 year olds (FDA)
• Stages of COVID-19 (AIDS Rev)
• B.1.1.529 attack rate in Australia (JID)
• Scent dogs (BMJ)
• Does Omicron affect pets? (CVMBS News)
• Paxlovid eligibility checklist (FDA)
• Supratherapeutic tacrolimus with nirmatrelvir/ritonavir (Op For Inf Dis)
• Is longer Paxlovid needed? (Reuters)
• How about Veklury? (Gilead)
• Fluvoxamine declined (FDA)
• Antigen positivity after isolation (MMWR)
• Inflammasome activation drives COVID-19 pathology (TWiV 900, Nature)
• PASC and viral antigen persistence in gut (Gastroenterol)
• GI symptoms and fecal shedding (Med)
• Contribute to ASTMH fundraiser at PW
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 901
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]